Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Mar;77(6):907–912. doi: 10.1038/bjc.1998.150

Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.

T Nakano 1, A P Chahinian 1, M Shinjo 1, A Tonomura 1, M Miyake 1, N Togawa 1, K Ninomiya 1, K Higashino 1
PMCID: PMC2150109  PMID: 9528833

Abstract

The relationship between interleukin 6 (IL-6) levels and clinical parameters was studied in 25 patients with malignant pleural mesothelioma. The serum levels of IL-6, C-reactive protein, alpha1-acid glycoprotein and fibrinogen were significantly higher in mesothelioma than in lung adenocarcinoma with cytology-positive pleural effusion. Serum IL-6 levels correlated with the levels of the acute-phase proteins. We demonstrated a high incidence of thrombocytosis (48%) and a significant correlation between platelet count and the serum IL-6 level. The level of IL-6 in the pleural fluid of patients with mesothelioma was significantly higher than in the pleural fluid of patients with adenocarcinoma, and was about 60-1400 times higher than in the serum. However, even higher levels of IL-6 in the pleural fluid and of thrombocytosis were found in patients with tuberculous pleurisy. These results indicate that large amounts of IL-6 from the pleural fluid of patients with mesothelioma leak into the systemic circulation and induce clinical inflammatory reactions. These profiles are not specific to mesothelioma as similar profiles are found in patients with tuberculous pleurisy. However, the detection of a markedly increased level of IL-6 in pleural fluid argues against a diagnosis of adenocarcinoma.

Full text

PDF
907

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akira S., Kishimoto T. The evidence for interleukin-6 as an autocrine growth factor in malignancy. Semin Cancer Biol. 1992 Feb;3(1):17–26. [PubMed] [Google Scholar]
  2. Bataille R., Jourdan M., Zhang X. G., Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest. 1989 Dec;84(6):2008–2011. doi: 10.1172/JCI114392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bielefeldt-Ohmann H., Fitzpatrick D. R., Marzo A. L., Jarnicki A. G., Musk A. W., Robinson B. W. Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model. J Interferon Cytokine Res. 1995 Mar;15(3):213–223. doi: 10.1089/jir.1995.15.213. [DOI] [PubMed] [Google Scholar]
  4. Bielefeldt-Ohmann H., Marzo A. L., Himbeck R. P., Jarnicki A. G., Robinson B. W., Fitzpatrick D. R. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother. 1995 Apr;40(4):241–250. doi: 10.1007/BF01519898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blay J. Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J. M., Moskovtchenko J. F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992 Jun 15;52(12):3317–3322. [PubMed] [Google Scholar]
  6. Castell J. V., Gómez-Lechón M. J., David M., Fabra R., Trullenque R., Heinrich P. C. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990 Nov;12(5):1179–1186. doi: 10.1002/hep.1840120517. [DOI] [PubMed] [Google Scholar]
  7. Chahinian A. P., Pajak T. F., Holland J. F., Norton L., Ambinder R. M., Mandel E. M. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med. 1982 Jun;96(6 Pt 1):746–755. doi: 10.7326/0003-4819-96-6-746. [DOI] [PubMed] [Google Scholar]
  8. De Pangher Manzini V., Brollo A., Bianchi C. Thrombocytosis in malignant pleural mesothelioma. Tumori. 1990 Dec 31;76(6):576–578. doi: 10.1177/030089169007600613. [DOI] [PubMed] [Google Scholar]
  9. Donna A., Betta P. G., Jones J. S. Verification of the histologic diagnosis of malignant mesothelioma in relation to the binding of an antimesothelial cell antibody. Cancer. 1989 Apr 1;63(7):1331–1336. doi: 10.1002/1097-0142(19890401)63:7<1331::aid-cncr2820630718>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  10. Duncan M. R., Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol. 1991 Oct;97(4):686–692. doi: 10.1111/1523-1747.ep12483971. [DOI] [PubMed] [Google Scholar]
  11. Gallo O., Gori A. M., Attanasio M., Martini F., Paola G., Storchi O. F., Abbate R. Acute-phase proteins and interleukin 6 serum level in head and neck cancer. Arch Otolaryngol Head Neck Surg. 1992 Dec;118(12):1366–1367. doi: 10.1001/archotol.1992.01880120092019. [DOI] [PubMed] [Google Scholar]
  12. Geiger T., Andus T., Klapproth J., Hirano T., Kishimoto T., Heinrich P. C. Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur J Immunol. 1988 May;18(5):717–721. doi: 10.1002/eji.1830180510. [DOI] [PubMed] [Google Scholar]
  13. Higashihara M., Sunaga S., Tange T., Oohashi H., Kurokawa K. Increased secretion of interleukin-6 in malignant mesothelioma cells from a patient with marked thrombocytosis. Cancer. 1992 Oct 15;70(8):2105–2108. doi: 10.1002/1097-0142(19921015)70:8<2105::aid-cncr2820700816>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  14. Holt I., Cooper R. G., Hopkins S. J. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest. 1991 Oct;21(5):479–484. doi: 10.1111/j.1365-2362.1991.tb01398.x. [DOI] [PubMed] [Google Scholar]
  15. Ishibashi T., Kimura H., Shikama Y., Uchida T., Kariyone S., Hirano T., Kishimoto T., Takatsuki F., Akiyama Y. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 1989 Sep;74(4):1241–1244. [PubMed] [Google Scholar]
  16. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988 Mar 3;332(6159):83–85. doi: 10.1038/332083a0. [DOI] [PubMed] [Google Scholar]
  17. Kishimoto T. The biology of interleukin-6. Blood. 1989 Jul;74(1):1–10. [PubMed] [Google Scholar]
  18. Klein B., Zhang X. G., Jourdan M., Boiron J. M., Portier M., Lu Z. Y., Wijdenes J., Brochier J., Bataille R. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw. 1990 Oct-Nov;1(4):193–201. [PubMed] [Google Scholar]
  19. Miles S. A., Rezai A. R., Salazar-González J. F., Vander Meyden M., Stevens R. H., Logan D. M., Mitsuyasu R. T., Taga T., Hirano T., Kishimoto T. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4068–4072. doi: 10.1073/pnas.87.11.4068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Monti G., Jaurand M. C., Monnet I., Chretien P., Saint-Etienne L., Zeng L., Portier A., Devillier P., Galanaud P., Bignon J. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment. Cancer Res. 1994 Aug 15;54(16):4419–4423. [PubMed] [Google Scholar]
  21. Motro B., Itin A., Sachs L., Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3092–3096. doi: 10.1073/pnas.87.8.3092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nagasawa T., Orita T., Matsushita J., Tsuchiya M., Neichi T., Imazeki I., Imai N., Ochi N., Kanma H., Abe T. Thrombopoietic activity of human interleukin-6. FEBS Lett. 1990 Jan 29;260(2):176–178. doi: 10.1016/0014-5793(90)80097-3. [DOI] [PubMed] [Google Scholar]
  23. Nakano T., Fujii J., Tamura S., Hada T., Higashino K. Thrombocytosis in patients with malignant pleural mesothelioma. Cancer. 1986 Oct 15;58(8):1699–1701. doi: 10.1002/1097-0142(19861015)58:8<1699::aid-cncr2820580820>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  24. Nijsten M. W., Hack C. E., Helle M., ten Duis H. J., Klasen H. J., Aarden L. A. Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. Surgery. 1991 Jun;109(6):761–767. [PubMed] [Google Scholar]
  25. Nijsten M. W., de Groot E. R., ten Duis H. J., Klasen H. J., Hack C. E., Aarden L. A. Serum levels of interleukin-6 and acute phase responses. Lancet. 1987 Oct 17;2(8564):921–921. doi: 10.1016/s0140-6736(87)91413-9. [DOI] [PubMed] [Google Scholar]
  26. Oliff A. The role of tumor necrosis factor (cachectin) in cachexia. Cell. 1988 Jul 15;54(2):141–142. doi: 10.1016/0092-8674(88)90543-0. [DOI] [PubMed] [Google Scholar]
  27. Ruffie P., Feld R., Minkin S., Cormier Y., Boutan-Laroze A., Ginsberg R., Ayoub J., Shepherd F. A., Evans W. K., Figueredo A. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol. 1989 Aug;7(8):1157–1168. doi: 10.1200/JCO.1989.7.8.1157. [DOI] [PubMed] [Google Scholar]
  28. Schmitter D., Lauber B., Fagg B., Stahel R. A. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer. 1992 May 8;51(2):296–301. doi: 10.1002/ijc.2910510220. [DOI] [PubMed] [Google Scholar]
  29. Stahel R. A., O'Hara C. J., Waibel R., Martin A. Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma. Int J Cancer. 1988 Feb 15;41(2):218–223. doi: 10.1002/ijc.2910410210. [DOI] [PubMed] [Google Scholar]
  30. Suzuki K., Miyashita A., Inoue Y., Iki S., Enomoto H., Takahashi Y., Takemura T. Interleukin-6-producing pheochromocytoma. Acta Haematol. 1991;85(4):217–219. doi: 10.1159/000204897. [DOI] [PubMed] [Google Scholar]
  31. Tartour E., Dorval T., Mosseri V., Deneux L., Mathiot C., Brailly H., Montero F., Joyeux I., Pouillart P., Fridman W. H. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer. 1994 May;69(5):911–913. doi: 10.1038/bjc.1994.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wirth P. R., Legier J., Wright G. L., Jr Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer. 1991 Feb 1;67(3):655–662. doi: 10.1002/1097-0142(19910201)67:3<655::aid-cncr2820670322>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  33. Yee C., Biondi A., Wang X. H., Iscove N. N., de Sousa J., Aarden L. A., Wong G. G., Clark S. C., Messner H. A., Minden M. D. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood. 1989 Aug 1;74(2):798–804. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES